CITIC Guojian Pharmaceutical

CITIC Guojian Pharmaceutical, now a core subsidiary of 3SBio, is a leading Chinese biopharmaceutical company focused on the development and commercialization of therapeutic monoclonal antibodies and fusion proteins. The company achieved significant prominence by launching Yisaipu, the first etanercept biosimilar in China, which remains a market leader for treating rheumatoid arthritis and ankylosing spondylitis. Its portfolio also includes Cipterbin (inetetamab), an innovative anti-HER2 antibody approved for metastatic breast cancer, and Xenopax for transplant rejection. Operating from a large-scale GMP-certified facility in Shanghai, the company maintains one of the largest mammalian cell culture capacities in China. Since its full acquisition by 3SBio in 2016, it has served as the primary biologics manufacturing and R&D hub for the group's expansion into oncology and autoimmune diseases.